



Co-funded by the European Union

ECL and its Access to Medicines Task Force



Ward Rommel, Toma Mikalauskaitė

Classified as internal/staff & contractors by the European Medicines Agency



ECL IN A NUTSHELL

- Founded in 1980
- 31 members in 26 countries in WHO European region (of which 21 EU MS)
- 8k staff, 300k volunteers, spend €750m a year to fight cancer & represent 580m citizens
- Members = non-profits operating across the whole cancer continuum & patient pathway
 - Cancer leagues are the main resource for the public for cancer control info & services
 - Members' Booklet
- Vision: "Europe free of cancer"
- Website | Twitter | LinkedIn | Facebook



ECL A2M TF


Our goals

The ECL Access to Medicines Task Force (A2M TF) aims to make safe and effective medicines available to all cancer patients in Europe, by insisting on accessibility, availability, affordability and increased transparency related to medicine prices, ultimately leading to sustainability of healthcare systems.
The A2M TF strongly believes in the power of constructive dialogue. We urge all stakeholders to push for accessibility to high quality treatments, improving both survival and the quality of life of cancer patients.

ACCESS

) MEDICINES SK FORCF

Policy papers



January 2023





Task Force Advocacy | Association of European Cancer Leagues - ECL

TO MEDICINES TASK FORCE

ACCESS

Policy dialogues



ACCESS

TO MEDICINES TASK FORCE

Classified as internal/staff & contractors by the European Medicines Agency

Position papers



ECL and EFPN recommendations for the revision of the EU legislation on medicines for rare diseases – March 2023 Infographic | Access to medicines for all patients with rare diseases – March 2022

ancer Leagues

EFPN

RICING NETWOR

ECL and Anticancer Fund recommendations for the revision of the EU general pharmaceutical legislation – March 2023

Task Force Advocacy | Association of European Cancer Leagues - ECL

ECL ACCESS TO MEDICINES TASK FORCE

ACCESS TO MEDICINES TASK FORCE

GET IN TOUCH WITH US!



CONTACT ECL toma@cancer.eu





